- ISIN
- US18507C1036
- CUSIP
- 18507C103
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Feb 12, 2020
Highlights
- Market Cap
- $504.07M
- Enterprise Value
- $532.30M
- EPS (TTM)
- -$1.01
- Total Revenue (TTM)
- $40.61M
- Gross Profit (TTM)
- $25.32M
- EBITDA (TTM)
- -$25.05M
- Year Range
- $8.27 - $30.10
- Target Price
- $18.00
- ROA (TTM)
- -31.11%
- ROE (TTM)
- -154.27%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CLPT Performance Chart
ClearPoint Neuro, Inc. (CLPT) is up 24.7% since the beginning of the year. At $17 per share, CLPT is trading 43.3% below its 52-week high of $30. Investors who bought $1,000 worth of CLPT shares 5 years ago would now be looking at an investment worth $892.
Loading charts...
Returns By Period
ClearPoint Neuro, Inc. (CLPT) has returned 24.71% so far this year and 51.51% over the past 12 months.
ClearPoint Neuro, Inc.
- 1D
- -4.00%
- 1M
- 49.13%
- YTD
- 24.71%
- 6M
- 16.77%
- 1Y
- 51.51%
- 3Y*
- 37.52%
- 5Y*
- -2.27%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CLPT Monthly Returns History
Based on dividend-adjusted daily data since Feb 12, 2020, CLPT's average daily return is +0.20%, while the average monthly return is +3.84%. At this rate, an investment would double in approximately 1.5 years.
Historically, 45% of months were positive and 55% were negative. The best month was Sep 2025 with a return of +107.7%, while the worst month was Nov 2025 at -37.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CLPT closed higher 48% of trading days. The best single day was Sep 24, 2025 with a return of +58.6%, while the worst single day was Mar 2, 2026 at -22.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.48% | -2.78% | -27.61% | 22.86% | 13.33% | 34.65% | 24.71% | ||||||
| 2025 | 13.52% | -16.84% | -18.11% | 21.03% | -17.93% | 1.10% | -12.90% | 0.87% | 107.72% | 6.56% | -37.73% | -5.39% | -11.05% |
| 2024 | 2.50% | -8.19% | 6.42% | -20.15% | 0.00% | -0.74% | 32.84% | 81.28% | -13.64% | 10.53% | -0.16% | 24.33% | 126.51% |
| 2023 | 12.28% | -10.83% | -0.47% | 24.64% | -26.81% | -5.97% | -5.11% | -15.43% | -13.77% | 9.78% | 4.73% | 17.88% | -19.83% |
| 2022 | -21.30% | -0.91% | 18.97% | -17.68% | 27.89% | 19.07% | 8.58% | -9.17% | -19.50% | -3.38% | -5.79% | -10.18% | -24.51% |
| 2021 | 48.71% | -0.89% | -9.74% | -1.47% | -11.57% | 3.64% | 16.45% | -15.11% | -5.94% | -5.75% | -17.93% | -18.28% | -29.39% |
Benchmark Metrics
ClearPoint Neuro, Inc. has an annualized alpha of 34.67%, beta of 1.36, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since February 12, 2020.
- This stock captured 111.27% of S&P 500 Index gains but only 87.12% of its losses - a favorable profile for investors.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 34.67%
- Beta
- 1.36
- R²
- 0.12
- Upside Capture
- 111.27%
- Downside Capture
- 87.12%
Return for Risk
Risk / Return Rank
CLPT ranks 62 for risk / return — better than 62% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ClearPoint Neuro, Inc. (CLPT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLPT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.53 | ||
| Sortino ratioReturn per unit of downside risk | -1.16 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.37 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | 0.73 | 2.78 | -2.05 |
| Martin ratioReturn relative to average drawdown | 1.13 | 12.44 | -11.31 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ClearPoint Neuro, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ClearPoint Neuro, Inc. was 84.62%, occurring on Nov 10, 2023. Recovery took 477 trading sessions.
The current ClearPoint Neuro, Inc. drawdown is 42.36%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -84.62%Nov 2023 | 2y 8mo | 1y 11mo | 4y 7moFeb 2021 - Oct 2025 |
2026 bear market2026 | -70.74%Mar 2026 | 5mo 22d | — | 8mo 17dOct 2025 - now |
2020 bear market2020 | -49.51%May 2020 | 3mo 1d | 5mo 2d | 8mo 3dFeb 2020 - Oct 2020 |
2020 correction2020 | -19.51%Nov 2020 | 16d | 9d | 25dOct 2020 - Nov 2020 |
2020 correction2020 | -10.75%Dec 2020 | 1d | 1d | 2dDec 2020 - Dec 2020 |
Drawdown Indicators
| CLPT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.62% | -56.78% | -27.84% |
Max Drawdown (1Y)Largest decline over 1 year | -70.74% | -9.10% | -61.64% |
Max Drawdown (3Y)Largest decline over 3 years | -70.74% | -18.90% | -51.84% |
Max Drawdown (5Y)Largest decline over 5 years | -79.96% | -25.43% | -54.53% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -42.36% | -1.80% | -40.56% |
Average DrawdownAverage peak-to-trough decline | -53.50% | -10.71% | -42.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 45.63% | 2.03% | +43.60% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ClearPoint Neuro, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ClearPoint Neuro, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CLPT relative to other companies in the Medical Devices industry. Currently, CLPT has a P/S ratio of 12.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CLPT in comparison with other companies in the Medical Devices industry. Currently, CLPT has a P/B value of 26.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CLPT
Add ClearPoint Neuro, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CLPT